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Dairy consumption, systolic blood pressure, and risk of 
hypertension: Mendelian randomization study
Mendelian Randomization of Dairy Consumption Working Group
ABSTRACT
ObjeCtive
To examine whether previous observed inverse 
associations of dairy intake with systolic blood 
pressure and risk of hypertension were causal.
Design
Mendelian randomization study using the single 
nucleotide polymorphism rs4988235 related to lactase 
persistence as an instrumental variable.
setting
CHARGE (Cohorts for Heart and Aging Research in 
Genomic Epidemiology) Consortium.
PartiCiPants
Data from 22 studies with 171 213 participants, and an 
additional 10 published prospective studies with 26 119 
participants included in the observational analysis.
Main OutCOMe Measures
The instrumental variable estimation was conducted 
using the ratio of coefficients approach. Using meta-
analysis, an additional eight published randomized 
clinical trials on the association of dairy consumption 
with systolic blood pressure were summarized.
results
Compared with the CC genotype (CC is associated with 
complete lactase deficiency), the CT/TT genotype (TT is 
associated with lactose persistence, and CT is 
associated with certain lactase deficiency) of LCT-13910 
(lactase persistence gene) rs4988235 was associated 
with higher dairy consumption (0.23 (about 55 g/day), 
95% confidence interval 0.17 to 0.29) serving/day; 
P<0.001) and was not associated with systolic blood 
pressure (0.31, 95% confidence interval −0.05 to 0.68 
mm Hg; P=0.09) or risk of hypertension (odds ratio 1.01, 
95% confidence interval 0.97 to 1.05; P=0.27). Using 
LCT-13910 rs4988235 as the instrumental variable, 
genetically determined dairy consumption was not 
associated with systolic blood pressure (β=1.35, 95% 
confidence interval −0.28 to 2.97 mm Hg for each 
serving/day) or risk of hypertension (odds ratio 1.04, 
0.88 to 1.24). Moreover, meta-analysis of the published 
clinical trials showed that higher dairy intake has no 
significant effect on change in systolic blood pressure 
for interventions over one month to 12 months 
(intervention compared with control groups: β=−0.21, 
95% confidence interval −0.98 to 0.57 mm Hg). In 
observational analysis, each serving/day increase in 
dairy consumption was associated with −0.11 (95% 
confidence interval −0.20 to −0.02 mm Hg; P=0.02) 
lower systolic blood pressure but not risk of 
hypertension (odds ratio 0.98, 0.97 to 1.00; P=0.11).
COnClusiOn
The weak inverse association between dairy intake 
and systolic blood pressure in observational studies 
was not supported by a comprehensive instrumental 
variable analysis and systematic review of existing 
clinical trials.
Introduction
Raised blood pressure is an important risk factor for 
cardiovascular disease and has been the top single con-
tributor to the global burden of morbidity and mortal-
ity, leading to 9.4 million deaths each year.1  In clinical 
trials, lowering blood pressure has been shown to be 
effective in reducing the incidence of cardiovascular 
disease.2  Each 5 mm Hg reduction in blood pressure is 
associated with a 20% lower risk of coronary heart dis-
ease and a 29% lower risk of stroke.3
Maintaining a healthy diet is critical for the preven-
tion of hypertension4 ; whether dairy products should 
be incorporated into such a diet is, however, controver-
sial. In epidemiological studies, the association of dairy 
consumption with blood pressure has been inconsis-
tent. Several observational studies have reported 
inverse associations of dairy consumption with systolic 
blood pressure and risk of hypertension5 6 7 ; however, 
such associations were not observed in other stud-
ies.8 9 10  Two meta-analyses of prospective cohort stud-
ies consistently indicated that dairy consumption was 
associated with lower systolic blood pressure and lower 
risk of hypertension.11 12 Owing to the observational 
nature of the studies included, the reported associa-
tions might not indicate causality.
In recent years, Mendelian randomization analysis has 
been widely used to assess potential causal estimates of 
various risk factors with health outcomes. This approach 
has the advantage over traditional observational studies 
of minimizing confounding by using genetic markers as 
instrumental variables of environmental risk factors. An 
SNP (single nucleotide  polymorphism) rs4988235 
upstream from the lactase persistence gene (LCT-13910) 
has been consistently related to dairy intake in multiple 
populations,13 14  representing a strong instrumental vari-
able for analyzing the causal relation between dairy 
intake and disease risk.
In this study, using data collected from 32 studies 
with 197 332 participants, we performed an  instrumental 
variable analysis to examine the possible causal effect 
of dairy consumption on systolic blood pressure and 
WhAT IS AlReAdy knoWn on ThIS TopIC
Observational studies showed that dairy intake was associated with lower systolic 
blood pressure and lower risk of hypertension
WhAT ThIS STudy AddS
Using a Mendelian randomization approach, we found that genetically determined 
dairy consumption was not associated with systolic blood pressure or risk of 
 hypertension
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risk of hypertension. In addition we conducted a 
meta-analysis to summarize the results of eight ran-
domized clinical trials assessing dairy intake interven-
tion on changes in systolic blood pressure.
Methods
study design and population
We used an instrumental variable approach to examine 
associations of dairy consumption with systolic blood 
pressure and risk of hypertension. We collected data 
from 22 observational studies with 171 213 participants 
within the CHARGE (Cohorts for Heart and Aging 
Research in Genomic Epidemiology) Consortium. All 
participants provided written informed consent. The 
web appendix describes the studies in the analysis.
To provide comprehensive evidence on associations 
of dairy intake with systolic blood pressure and risk of 
hypertension, we conducted a systematic review of pre-
viously published cohort studies and randomized clin-
ical trials. In the web appendix, we describe the process 
of the systematic review in detail.
Dairy consumption
Dairy products included skim/low fat milk, whole milk, 
ice cream, yogurt, cottage/ricotta cheese, cream cheese, 
other cheese, and cream. In most of the studies, dairy 
intake was self reported by food frequency question-
naire. We calculated total dairy consumption as the 
sum of all dairy categories (see table 1 in the web appen-
dix for a detailed description of dairy consumption in 
the included studies).
Outcome measures
The outcome of our Mendelian randomization included 
systolic blood pressure and risk of hypertension. Given 
that systolic blood pressure is superior to diastolic blood 
pressure as a major risk factor of cardiovascular disease, 
we used systolic blood pressure as the main outcome in 
our analysis (see table 1 in the web appendix for the 
detailed measurement of systolic blood pressure in the 
included studies). For participants taking antihyperten-
sive drugs, we added 15 mm Hg to systolic blood pres-
sure to adjust for treatment effects.15-17 Hypertension was 
defined as a systolic blood pressure of 140 mm Hg or 
higher or current use of antihypertensive drugs.
snP rs4988235
Table 1 in the web appendix shows genotyping plat-
forms, genotype frequencies, Hardy-Weinberg equilib-
rium P values, and call rates for lactase persistence SNP 
rs4988235. The SNP rs4988235 was not genotyped or 
imputed in two studies; proxy SNPs (rs309137: r2=0.77; 
rs1446585: r2=1.00) were used instead.
statistical analyses
We initially conducted statistical analyses within each 
included study in accordance with a standard analysis 
plan. As lactase persistence is inherited as a dominant 
trait,3 we used dominant models (CC v CT/TT genotype) 
to examine associations of LCT-13910 rs4988235 with 
dairy intake, systolic blood pressure, and risk of t
ab
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 hypertension adjusting for baseline age, sex, ethnicity, 
and region. We examined associations of dairy con-
sumption with systolic blood pressure and risk of hyper-
tension using linear or logistic models adjusting for 
baseline age, body mass index, blood pressure, smoking 
status, physical activity, total energy intake, alcohol 
consumption, sex, ethnicity, region, and years of fol-
low-up. For results collected from all studies using lin-
ear or logistic models, we combined results across 
studies using random effects models. We meta- analyzed 
the results of observed associations of dairy intake with 
systolic blood pressure and risk of hypertension within 
the CHARGE Consortium with results extracted from 
published cohort studies. The effect of dairy intake on 
systolic blood pressure from published randomized clin-
ical trials was also meta-analyzed using a random 
effects model. Statistical heterogeneity across studies 
was assessed by Cochrane Q test, with P<0.1 indicating 
 significant between study heterogeneity. In addition, we 
calculated the I2 statistic to evaluate the percentage of 
heterogeneity that was due to between study  variation.18
After pooling the association between LCT-13910 
rs4988235 and dairy intake across studies by meta-anal-
ysis, we quantified the strength of the single SNP as an 
instrumental variable by Z statistic and P value of the 
pooled effect estimate. We considered LCT-13910 
rs4988235 a strong instrumental variable if the Z statis-
tic was more than 3.2 or the P value was less than 
0.0016, which was equivalent to an F statistic greater 
than 10.19 20  We used the instrumental variable ratio 
method to estimate the possible causal relation of dairy 
consumption with systolic blood pressure and risk of 
hypertension. The instrumental variable estimate was 
calculated as the ratio of the association of the instru-
mental variable with outcome to the association of the 
exposure with outcome. We estimated the variance of 
the instrumental variable ratio using first order Taylor 
expansion.21
We further conducted stratified analysis on the causal 
estimates of dairy intake with systolic blood pressure 
and risk of hypertension by frequency of CC alleles 
(≤12%, >12%), region or country (northern Europe, 
southern Europe, US), race (white, other), study design 
(cross sectional, prospective), and measurement of sys-
tolic blood pressure (self reported, clinical). We used 
metaregression to evaluate effect modification by each 
study level characteristics. In sensitivity analyses, we 
applied instrumental variable analysis within each 
study and combined the  instrumental variable estimates 
through meta-analysis; we repeated our analyses using 
additive (we assumed 0, 1, and 2 for TT, CT, and CC 
alleles) and recessive models (CC/CT v TT). We con-
ducted restriction analyses by excluding studies that 
used proxy SNPs, studies that used LCT-13910 rs4988235 
in Hardy-Weinberg disequilibrium, or studies where 
LCT-13910 rs4988235 was not statistically significantly 
associated with higher dairy intake.
All meta-analyses were conducted at Harvard TH 
Chan School of Public Health using Stata version 11.2 
(STATA Corp, College Station, TX).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
We included 22 studies with 171 213 participants from 
the CHARGE (Cohorts for Heart and Aging Research in 
Genomic Epidemiology) Consortium. Table 1 shows the 
baseline characteristics of the studies. Of the 22 studies, 
nine were conducted in the US, nine in countries in 
northern Europe, three in countries in southern Europe, 
and one in Australia. The frequency of CC alleles varied 
across studies. In most of the studies, participants were 
Fig 1 | association of baseline dairy consumption (serving/day) with systolic blood 
pressure in observational cohort studies. linear regression was used in collaborative 
cohorts adjusted for sex, ethnicity, region or country, and years of follow-up, as well as for 
age, body mass index, blood pressure/hypertension, smoking status, physical activity, 
total energy intake, and alcohol consumption at baseline
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white, and dairy intake was assessed prospectively 
before measuring systolic blood pressure.
By conducting a systematic review, we additionally 
identified 10 published cohort studies with 26 119 par-
ticipants and eight randomized clinical trials with 735 
participants. Figure 1 in the web appendix shows the 
flowchart of study selection. The clinical trials exam-
ined the effect of dairy intake on systolic blood pressure 
over one month to 12 months of interventions.22-29  In the 
cohort studies, seven assessed systolic blood pressure 
as the outcome5-10 30 31  and five used hypertension as the 
outcome.5 30-33 Tables 2 and 3 in the web appendix show 
the characteristics of the published trials and cohorts.
In observational analysis, each serving/day increase 
in dairy consumption was associated with lower sys-
tolic blood pressure (β=−0.11, 95% confidence interval 
−0.20 to −0.02 mm Hg; P=0.02) and was not associated 
with a lower relative risk of hypertension (odds ratio 
0.98, 95% confidence interval 0.97 to 1.00; P=0.11) (figs 1 
and 2 ). In the randomized clinical trials, however, dairy 
intake did not show a significant effect on changes in 
systolic blood pressure over one month to 12 months of 
interventions (comparing intervention with control 
group: β=−0.21, −0.98 to 0.57 mm Hg; P=0.60) (fig 3). No 
publication bias of included cohorts and clinical trials 
was found (systolic blood pressure in cohorts: Egger’s 
test P=0.51; hypertension in cohorts: P=0.46; random-
ized clinical trials: P=0.33) (fig 2 in the web appendix).
Compared with the CC genotype, the CT/TT genotype 
of LCT-13910 rs4988235 was associated with higher 
dairy consumption (0.23 (95% confidence interval 0.17 
to 0.29) serving/day (about 55 g/day); P<0.001), and the 
Z statistic was 7.51, showing that the instrumental vari-
able was strong and valid (fig 4). However, significant 
heterogeneity was found across studies (I2=80.0%; 
P<0.001 for heterogeneity). Compared with the CC gen-
otype, the CT/TT genotype of LCT-13910 rs4988235 was 
not associated with systolic blood pressure (0.31, −0.05 
to 0.68 mm Hg; P=0.09) or risk of hypertension (odds 
ratio 1.01, 95% confidence interval 0.97 to 1.05; P=0.27) 
(figs 5 and 6). Using LCT-13910 rs4988235 as the instru-
mental variable, we estimated that genetically deter-
mined dairy consumption was not associated with 
systolic blood pressure (β=1.35, 95% confidence interval 
−0.28 to 2.97 mm Hg for each serving/day) or risk of 
hypertension (odds ratio 1.04, 0.88 to 1.24).
To explore sources of heterogeneity in the association 
of LCT-13910 rs4988235 with dairy intake, we conducted 
stratified analyses by region or country, frequency of the 
CC genotype, race, study design, and measurement of 
systolic blood pressure. We classified Denmark, the Neth-
erlands, Sweden, and Finland as northern  European 
countries and Italy, Spain, and France as southern Euro-
pean countries. Among studies with a CC genotype fre-
quency of 12% or less, or studies conducted in northern 
European countries, we found no heterogeneity of LCT-
13910 rs4988235 with dairy intake, and the instrumental 
variable remained strong in both subgroups. Genetically 
determined dairy consumption was unrelated to systolic 
blood pressure and risk of hypertension within each 
 stratum, which was consistent with the main finding 
Fig 3 | association of baseline dairy consumption (serving/day) with systolic blood 
pressure in randomized clinical trials
Fig 2 | association of baseline dairy consumption (serving/day) with relative risk of 
hypertension in observational cohort studies. logistic regression was used in 
collaborative cohorts adjusted for sex, ethnicity, region or country, and years of 
follow-up, as well as for age, body mass index, blood pressure/hypertension, smoking 
status, physical activity, total energy intake, and alcohol consumption at baseline
the bmj | BMJ 2017;356:j1000 | doi: 10.1136/bmj.j1000
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(table 2). No effect modification on causal estimates was 
found by CC frequency, region or country, race, study 
design, and systolic blood pressure measurement.
In sensitivity analyses, we applied the instrumental 
variable analysis within each study and combined the 
instrumental variable estimates using meta-analysis. The 
results were consistent with the main findings (fig 3 in the 
web appendix). We examined the associations of dairy 
consumption with systolic blood pressure and risk of 
hypertension by modeling the LCT-13910 genotype in 
recessive and additive inheritance manner (figs 4 and 5 in 
the web appendix). Genetically determined dairy con-
sumption was not associated with systolic blood pressure 
or risk of hypertension using the recessive model, and it 
was weakly associated with higher systolic blood pressure 
using the additive model (table 4 in the web appendix).
In restriction analysis, the instrumental variable esti-
mates were consistent with the main findings when 
excluding studies that used proxy SNPs, studies that 
used LCT-13910 rs4988235 in Hardy-Weinberg disequi-
librium, or studies where LCT-13910 rs4988235 was not 
statistically significantly associated with higher dairy 
intake using dominant models.
discussion
In this study, using Mendelian randomization analysis 
in 32 studies (22 observational studies, 10 previously 
published cohort studies) with 197 332 participants, we 
examined the potential causal effect of dairy consump-
tion on systolic blood pressure and risk of  hypertension. 
Using the LCT-13910 gene variant affecting lactase per-
sistence as the instrumental variable, our study showed 
that genetically determined dairy intake did not affect 
systolic blood pressure or risk of hypertension. Further-
more, a meta-analysis of the results from published ran-
domized clinical trials showed that dairy consumption 
had no effect on changes of systolic blood pressure in 
response to interventions over one month to 12 months.
strengths and weaknesses of this study
Our study has several strengths. First, we carried out a 
large instrumental variable analysis on the causality of 
dairy intake on systolic blood pressure and hyperten-
sion. The large sample size provided us with enough 
power to estimate the causal effect of dairy intake on 
systolic blood pressure. Second, the single nucleotide 
polymorphism (SNP) rs4988235 for lactase persistence 
is a well established variant associated with dairy 
intake, with a solid biological basis, and is therefore a 
highly valid instrumental variable. Third, we 
 summarized published randomized clinical trials on 
dairy consumption with systolic blood pressure. 
Although clinical trials have shorter follow-up time 
than cohort studies, they still provided further support-
ive evidence to the instrumental variable results.
Our study has several limitations. First, given the vari-
ability of the CC allele across studies and the different 
prevalence of hypertension across countries, population 
stratification might exist. However, as most of the studies 
included were genetically homogeneous, we performed 
instrumental variable analysis within each study first and 
Fig 4 | association of snP rs4988235 with dairy consumption using dominant model (Ct/tt v CC 
genotype). linear regression adjusted for baseline age, sex, ethnicity, and region or country
Fig 5 | association of snP rs4988235 with systolic blood pressure using dominant model (Ct/tt v CC 
genotype). linear regression adjusted for baseline age, sex, ethnicity, and region or country
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combined the instrumental variable results through 
meta-analysis. The instrumental variable results were 
consistent with the main findings. Second, the pleiotropic 
effect of SNP rs4988235 is not known. However, SNP 
rs4988235 was located in the MCM6 gene upstream from 
LCT-13910, and neither gene has been found to have addi-
tional biological function besides lactase persistence.13 
Third, dairy consumption was self reported by question-
naire and might be affected by measurement errors. If 
measurement errors were random, the observed associa-
tions would be biased to the null. However, the results for 
instrumental variable estimates would not be biased, 
although the confidence interval might be larger. Fourth, 
we included total dairy intake as the main exposure; how-
ever, lactase content differs between dairy products. For 
example, Swiss cheese and mozzarella contain trivial 
amounts of lactase. Similar to the measurement error of 
dairy intake, the variability in lactase content of dairy 
products might not bias the instrumental variable esti-
mates but might widen the confidence intervals. Fifth, 
several studies examined dairy consumption and systolic 
blood pressure using a cross sectional study design, and 
even if instrumental variable analysis was used this might 
result in reverse causation. However, no statistically sig-
nificant effect modification by study design was found in 
stratified analysis, indicating that reverse causation 
caused by study design might be  minimal.
strengths and weaknesses in relation to other 
studies
In our study we observed an inverse association between 
dairy intake and systolic blood pressure. Consistently, 
cross sectional studies showed an inverse association 
between dairy intake and systolic blood pressure.34-36 
Previous cohort studies have been summarized in two 
meta-analyses.11 12  One meta-analysis involving approx-
imately 45 000 participants showed that dairy products 
were associated with lower risks of raised systolic blood 
pressure.11  In line with this, another meta-analysis, 
which included nine cohort studies with a sample size of 
57 256, found an inverse association between dairy foods 
and risk of  hypertension.12  However, in both meta-anal-
yses, the associations of high fat dairy products, includ-
ing whole milk, cream, and cream cheese, and low fat 
dairy products, including skim milk and yogurt with 
systolic blood pressure were inconsistent. In the two 
published meta-analyses, the observed inverse associa-
tion was mainly due to consumption of low fat dairy 
products.11 12  Furthermore, a meta-analysis summarizing 
14 clinical trials found that probiotic fermented milk, 
including yogurt, resulted in a statistically significant 
reduction in systolic blood pressure.37  Clinical trials also 
showed that tripeptides and peptides derived from milk 
have hypotensive effects in prehypertensive and hyper-
tensive participants.38 39
Possible explanations and implications
Compared with the CC genotype, the CT/TT genotype 
was associated with 0.23 serving/day (about 55 g/day) 
higher dairy intake. In previous cohort studies, a 55 g/
day increment in dairy intake was estimated to be sta-
tistically significantly associated with 0.03 mm Hg 
lower systolic blood pressure, and 1%, 2%, and 1% 
lower risks of hypertension,12  type 2 diabetes,40  and 
cardiovascular disease,41  respectively. However, in our 
study, the CT/TT genotype was associated with a 0.31 
mm Hg higher systolic blood pressure, and genetically 
determined dairy consumption did not decrease sys-
tolic blood pressure or risk of hypertension using 
instrumental variable estimation. Moreover, the 
meta-analyzed results of clinical trials showed that 
dairy intake had no effect on changes in systolic blood 
pressure. There could be two reasons that the reported 
associations from observational studies were inconsis-
tent with our instrumental variable results. First, even if 
yogurt and specific nutrients in dairy such as milk pep-
tides have antihypertensive effects, specific dairy prod-
ucts such as yogurt only compose a small fraction of 
total dairy products and could not explain the general 
observational association between dairy intake and 
outcome. Second, higher low fat dairy intake was more 
likely to be associated with a healthy diet and lifestyle.42 
Therefore, the observed inverse association of particu-
larly low fat dairy intake with systolic blood pressure 
might be due to confounding of intake of other food 
items and a healthy lifestyle. However, as one funda-
mental assumption for the instrumental variable to be 
valid is that the instrumental variable is associated with 
the outcome only through the exposure under study,43 
Fig 6 | association of snP rs4988235 with relative risk of hypertension using dominant 
model (Ct/tt v CC genotype). logistic regression adjusted for baseline age, sex, ethnicity, 
and region or country
the bmj | BMJ 2017;356:j1000 | doi: 10.1136/bmj.j1000
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we could not separate the effect of individual dairy 
products in our study to further explain the inconsis-
tency between observational and instrumental results 
using the current instrumental variable. And it is diffi-
cult to find a specific instrumental variable for each 
dairy product.
To tackle the heterogeneity of the association 
between SNP rs4988235 and dairy intake across studies, 
we conducted stratified analysis by CC frequency and 
region or country. SNP rs4988235 was consistently asso-
ciated with higher dairy intake across subgroups, show-
ing the robustness of our instrumental variable. No 
heterogeneity was found among studies conducted in 
northern Europe or among studies with a CC frequency 
of 12% or less, perhaps because these populations con-
sume a relatively high amount of dairy products,44  and 
SNP rs4988235 was found to be associated completely 
with lactase persistence in north Europeans.13 No asso-
ciations of genetically determined dairy intake with 
systolic blood pressure and risk of hypertension were 
found in both subgroups, which were consistent with 
our main finding.
Conclusion
The weak inverse association between dairy intake and 
systolic blood pressure in observational studies was 
not supported by our comprehensive instrumental 
variable analysis and systematic review of existing 
clinical trials.
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